current status on marine products with reversal effect on cancer multidrug resistance现状对海洋产品和逆转肿瘤多药耐药性的影响.pdfVIP

Mar. Drugs 2012, 10, 2312-2321; doi:10.3390/m OPEN ACCESS Marine Drugs ISSN 1660-3397 /journal/marinedrugs Review Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance Ioana Abraham 1,†, Khalid El Sayed 2, Zhe-Sheng Chen 1,* and Huiqin Guo 3,†,* 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; E-Mail: ioana.abraham@ 2 Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA; E-Mail: elsayed@ 3 Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, China † These authors contributed equally to this work. * Authors to whom correspondence should be addressed; E-Mails: guohuiqin2@163.com (H.G.); chenz@ (Z.-S.C.); Tel.: +86-1391-065-8671 (H.G.); +1-718-990-1432 (Z.-S.C.). Received: 28 August 2012; in revised form: 13 September 2012 / Accepted: 29 September 2012 / Published: 19 October 2012 Abstract: The resistance of tumor cells to a broad range of anticancer agents continues to be a problem for the success of cancer chemotherapy. Multidrug resistance (MDR) is due in part to three drug transporter proteins: ABCB1/P-glycoprotein (P-gp), ABCC1/multidrug resistance protein 1 (MRP1) and ABCG2/breast cancer resistance protein (BCRP). These transporters are part of the ATP-binding cassette (ABC) superfamily, whose members function as ATP-dependent drug-efflux pumps. Their activity can be blocked by various drugs such as verapamil